SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genaissance Pharmaceuticals (GNSC)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who started this subject1/9/2004 9:21:46 AM
From: nigel bates   of 183
 
Genaissance Pharmaceuticals Analyzed Samples for United States Department of Agriculture in Mad Cow Disease Investigation
Friday January 9, 7:01 am ET
- Opportunity for Entry into Animal DNA Testing Market -

NEW HAVEN, Conn., Jan. 9 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) announced today that it had completed an analysis of DNA samples for the United States Department of Agriculture (USDA) as part of the USDA's effort to trace the origin of the animal infected with bovine spongiform encephalopathy or Mad Cow disease.

ADVERTISEMENT"We were honored that the USDA asked us to analyze these very important samples," said Gerald F. Vovis, Ph.D., Executive Vice President and Chief Technology Officer of Genaissance Pharmaceuticals. "We had our personnel standing by to receive the samples when they arrived by courier and then worked around the clock to ensure that the results were available as rapidly as possible."

"We see the use of DNA testing for animal identity and traceability as a new market opportunity for us and another step in the execution of our strategy to build a profitable base services business while developing proprietary products based on our HAP(TM) Technology," Dr. Vovis continued. "We believe that we have the experience to be a major player in this arena because we have an accredited genotyping laboratory that has a high-throughput process for analyzing DNA, including a proprietary laboratory information management system, the necessary robotics and microarray instrumentation. During the past year, we used this platform to generate over 8,000,000 DNA analysis results for our customers."

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and pharmacogenomic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut. Visit the company's website at www.genaissance.com.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext